Systemically administered chemotherapy is not very effective in the treatment of primary or
metastatic brain tumours. An important reason for this low efficacy is insufficient drug …

There is no accepted standard of care for the chemotherapy treatment of metastatic brain
tumors, which has been generally limited to lipophilic alkylators, which may not have efficacy …

Simple Summary The blood–brain tumor barrier (BBTB) represents a major obstacle for the
delivery of anticancer drugs to tumors of the central nervous system. Various approaches …

Treatment of brain tumors with chemotherapy is limited mostly because of delivery
impediments related to the blood-brain barrier (BBB). For gliomas, the most common and …

A prerequisite for the efficacy of any cancer drug is that it reaches the tumor in therapeutic
concentrations. This is difficult to accomplish in most systemic solid tumors because of …

Standard chemotherapy administered systemically has a limited efficacy in the treatment of
brain tumors. One of the major obstacles in the treatment of brain neoplasias is the …

Brain tumors are characterized by very high mortality and, despite the continuous research
on new pharmacological interventions, little therapeutic progress has been made. One of the …

The presence of barriers, such as the blood–brain barrier (BBB) and brain–tumor barrier
(BTB), limits the penetration of antineoplastic drugs into the brain, resulting in poor response …

The blood-brain barrier (BBB) is a gate that controls the influx and efflux of a wide variety of
substances and consequently restricts the delivery of drugs into the central nervous system …

The efficacy of chemotherapy for malignant primary or metastatic brain tumours is still poor.
This is at least partly due to the presence of the blood-brain barrier (BBB). The functionality …